Total Funding
12
Total FundingVenture - Series Unknown raised
Growth Score
pts
Heat Score
10 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
Arisaph Pharmaceuticals is focused on the development of therapies for cancer, cardiovascular disease, and diabetes.
William Bachovchin: Co-Founder, Executive Vice President and Chief Scientist
Christopher P. Kiritsy: Founder and President and CEOPast Role: KOS Pharmaceuticals, Executive Vice President of Corporate Development and Chief Financial Officer
About the Company
Arisaph Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing therapies for cancer, cardiovascular disease, and diabetes. Its products include dipeptidylpeptidase IV inhibitors, stable GLP-1 agonists, HDL modulators and plaque reducers, and tumor activated pro-soft drugs.
The company was founded in 1999 and is based in Boston,
Massachusetts.
